CalvinJCohenMDM.Sc.

Internal Medicine • Boca Raton, FL

HIV/AIDS Medicine

Executive Director, Gilead Sciences, Global HIV Medical Affairs

Join to view full profile

Dr. Cohen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cohen's full profile

Already have an account?

Office
Gilead Sciences Inc
Boca Raton, FL 33496
Is this information wrong?

Education & Training

Boston University Medical CenterChief Residency, Internal Medicine, 1988
Harvard Medical SchoolFaculty Devefopment and Feìlowship Program in Generaî Inïernaì Medicine, 1988 - 1990
Harvard School of Public HeaìthM.Sc, Science Health Policy, 1990
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1986 - 1988
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1985 - 1986
Albert Einstein College of MedicineClass of 1985
Cornell UniversityBA, Psychology, 1972 - 1976

Certifications & Licensure

MA State Medical License 1988 - 2015

Awards, Honors, & Recognition

Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2015
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
The Robert H. Ebert Teaching Award Harvard Vanguard Medical Assoc. and the Harvard Pilgrim Hearth Care, 2006
Community Recognition AEDS Action Committee, 1998
Outstanding Physicians Harvard Vanguard Madicaì Assoc, 1997
Champions of the Search 1995
Distinction for Research in Cardioiogy AECOIVI, 1985
Aipha Omega Alpha 1985
Upjohn Award for Exceilence in Medical Training 1985
Quill and Dagger Honor Society 1975
Join now to see all

Clinical Trials

A Study of Anal Cancer Development in HIV Infected People Start of enrollment: 2005 Feb 01
Completed
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) Start of enrollment: 2006 Jun 01
Terminated
Phase 4
Respiratory Virus Outpatient Study (FLU 002 Plus) Start of enrollment: 2009 Aug 01
Completed
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days Start of enrollment: 2008 Nov 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

1651 citations
CD4+ count-guided interruption of antiretroviral treatment.
Wafaa El-Sadr, Jens D Lundgren, James D. Neaton, Fred M. Gordin, Dominic Abrams
The New England Journal of Medicine. 2006-11-30
147 citations
Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
D. W. Cameron, Anthony J. Japour, Yi Xu, Ann Hsu, John W. Mellors
AIDS. 1999-02-04
406 citations
Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
D. William Cameron, Margo Heath-Chiozzi, Sven A. Danner, Calvin J. Cohen, Stephen Kravcik
Lancet. 1998-02-21

Journal Articles

A nuclease from animal serum which hydrolyzes double-stranded RNA.
Stern, R, Biochem. Biophys. Res. Commun. 41: 608-614
Anomalous effects of heterologous serum on interferon production in mice.
Friedman, R.M., Barth, R.F., Stern, R, Nature New Biol. 230: 17-18
Chromatography of synthetic polymers of ribonucleic acid on columns of benzoylated diethylaminoethyl-cellulose.
Stern, R, Biochemistry 10: 2963 -2968

Books/Book Chapters

HIV Essentials.
Chapter: Royai Oak
Sax PE, Cohen CJEditors: Kurìtzkes DR.Mi Physicians’ Press
Understanding Triais in Libman.
Freedberg KA and Cohen CJEditors: H, RA.M Infection, Boston, Massachusetts

Abstracts/Posters

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initiai treatment of HIV infection
Elion R, Cohen C, et ai. on behalf ofthe Study Team, AIDS. 25(15):1881-6. Sep 24, 2011. PMD 21811136.
Riipivirine versus efavirenz with two backcrround nucleoside or nucieotide reverse transcriptase inhibitors in treatmeniœnaive admits infected with HIV-1 (THREVE): a p...
Cohen C, et ai. on bebahC ofthe THRIVE study group, The Lancet. 378(9787):229-237. Jui 16, 2611. Elsevier Properties SA. PMID: 21763935
Cost-Effectiveness of Nucleoside Reverse Trenscriptase Inhibitor Pairs in Efavirenz-Based Regimentsfor Treatment~Native Adults with HN Infection in the United States.
Brogan AJ, Telbird SE, Cohen C, Value in Healfh. 14(5):657-664. Eisevier Properties SA.
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
D, Cohen C, et al, Trials. 12(3):131-140. May-Jun 2011. Thomas Land. 21684853
The effects of enfuvirtide therapv on body composition and metabolic parameters over 48 weeks in the TORO bodv substudy.
Cooper DA, etal. TORO 1 and TORO 2 Study Groups, HIV Med. 12(1):31-39. Jan 2011. doi: 10.1111lj.14681293.201G.O0845.x. PNHD: 2049"f"250.
Similar virologic and immunoioqic efficacy with fosamprenavir boosted with 100 mg or 200 ma of ritonavir in HI\/-infected patients: results of the LESS trial.
Cohen C, et ai, HIV Clinical Trials. Sep-Oct 2010. 21126954
Relationshig between mesma eroiease inhibitor Concentrations and iioid eievations in HIV patients on a doubleboosted protease inhibitor reqimen (saeuineuir/iopinavir/r...
Rhee MS, Heiìinger JA, Shebleáiaii S, Cohen CJ, Greenblatt DJ, Journal of Clinical Pharmacoiogy. 50(4):392«400. Apr 2010. Epub Jan 23, 2010 PMID: 20097936.
Tai Chi for osteopenic women: desien and rationale of a pragmetic randomized controlled trial.
Wayne PM, Buring JE, Davis RB, Connors ENI, Bonato P, Patritti B, Fischer M, Yeh GY, Cohen CJ, et al, Mar 1, 2010. PMID: 20193083
Low-abundance HIV species and their impact on mutationai profiles in patients with viroloaical failure on once~daily abaoavir/Iamivudine/zidovudine and tenofovir.
Ress LL, Rouse E, Gerondelis P, DeJesuS E, Cohen C, et al, Journal of An?imicrobia! Chemotherapy. 65(2). Feb 2010*
COl_40263 Study Team. Modulation of K65R selection bv zidovudine inclusion: analysis of HIV resistance selection in subjects with vireleglc failure recelving once-dail...
Ross L, Elion R, Lanier R, Dejesus E, Cohen C, et al, AIDS Research and Human Retrovíruses. 25(7):665672. Jul 2009. PMiD: 19563238.
Seiect undates from the 181:11 CROE: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin2 use.
Boyie BA, Cohen CJ, et ai, The AIDS Reader. 19(4):158-180. Apr 2009n A Cliggott Pubfication. PNUD: 19388184
Low-Level in HIV-1 Infection: Consequences and inplications for Switching to a New Reqimen.
Cohen CJ, HIV Clinical 10(2):E16~24. Mar«Apr2009. Review. PMID: 19487182
The ARTEMIS trial: once-daily darunavir/ritonavir in the management of treatment-naïve.
Cohen CJ, HN-infected patientst HIV Therapy. 3(2):121133. Mar 2009.
Prescribing and usinq self-iniectabie antiretrcvirais: How concordant are physician and patient perspectives?
Home R, Kovacs C, Katiama C, Ciotat B, Fumaz CR, Youie NI, Kuiasegaram R, Fisher M, Cohen CJ, et al, AIDS Research and Therapy. 6: 2. Feb 5, 2009. PMID: 19196474.
and safety of siravirine (TMC125) in treatment-experienced HN-1infected patients: 48-Week results of a phase lib trial.
Cohen Cd, et al, AIDS. 23(3)!!-23-6. dan 28, 2009. PMED: 19114852
Antiretroviraf Therapy Update from the 48th :GAAG/46* Annual Meem.
Boyle BA, Cohen CJ, DeJesus, E, et ai, The AIDS Reader. 19(1);570-579. Jan 2009. A Cnggou Pmicarion. Pn/nn;
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-base regimen.
Fox Z, Phiiìips A, Cohen C, et al. on behaìf ofthe SMART Study Group., AIDS. 22(17):2279-2289. Nov 12, 2068. Wolters Kiuwer Health.
The FOTO study: results support the safety of a 2-day break on efaviranz-based antiretroviral therapy.
Cohen CJ, Colson AE, Pierone G, Dek-asus E, Kinder F, Eiion R, Skiest il), Habel A, Jensen J, J Garb, Schfager HS, Journal ofthe lm‘ernationalAlDS Society. 11 (Suppi. Nm/10, 2008.
Virologic response to lopinavir-ritonavir~based antiretrovirali regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.
Grant P, Wong EC, Rode R, Shafer R, De Luca A, Nadler J, Hawkins T, Cohen C, Harrington R, Kempf D, Zolopa A, Antimicrobial Agents and Chemotherapy. 52(‘11):4050»405ô. Nov 2008. Epub Aug 18, 2008. PMID: 1871091
Antiretrovira Treatment Update from the 17th Entemationai AIDS Conference.
Boyie BA, Cohen CJ, DeJesus E, etai, The AIDS Reader. Nov 2068. A Pubiicatìon.
MOTNATE Study Teams. for previously treated patients with R5 HW-1 infection.
RM, et ai, New England Journal of Medicine 359(14):1429«‘i441. Oct 2, 2008. PMED: 18832244.
MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroug analyses of maraviroo in previously treated R5 HIV-1 infection.
Fätkenheuer G, et ai, New England Journal of Medicine. 359(14):1442’l455. Oct 2, 2008. PMED; 18832245
Loncfmierm safely and effects of tesamoielin, a orowtn hormone~releasiny factor analoous.
Fslutz .5, Alias S, l\/lsmputu JC, et al, . Lippincott Williams & Wilkins Publishers
Evaluation of Efficacy, Safety, Pharmacokinetics, and Adherence in HN-1-lnfecteg, AntEretroviral~Native Patients Treated with Ratonaviwpoosted Atazanavir Plus Fixecf-D...
Elìon R, Cohen CJ, Ward E), et ai. on behalf of the BATON Study Group, Thomas Land Publishers. PNUD: 18753116
Determination of the underlying cause of death In three multicenter international Clinical trials.
Lifson AR, et ai, INSIGHT Cause of Death Writing Group., HIV Clinical Triafs. 9(3):i77»85. May-Jun 2008. PMID: 18547904
Join now to see all

Lectures

SingIe~tab|et, fixed-dose regimen of eiviteqravir/emtricitabinelitenofovir disoproxii rumarate/GS-9350 achieves a high raie of virologac suppression and GS-9350 is an ...
17th Conference on Retroviruses and Opporïunistic Infections (CROi); Feb 16«19, 2610; San Francisco,

Other

Primer on interpretation of HIV drug resistance testing
Cohen CJ, Gallant JE
http://www.uptodate.com/contents/primer-on-interpretation-of-hiv-drug-resistance-testing
UpToDate, Wolters Kluwer Health - 2012-09-20